Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Sequential Design Study to Evaluate the Drug-drug Interaction between TAK-438 and Low-dose Aspirin or NSAIDs (Loxoprofen Sodium, Diclofenac Sodium or Meloxicam) in Healthy Male Subjects

Next Previous
X
Search
Trial Profile

A Phase 2, Open-Label, Sequential Design Study to Evaluate the Drug-drug Interaction between TAK-438 and Low-dose Aspirin or NSAIDs (Loxoprofen Sodium, Diclofenac Sodium or Meloxicam) in Healthy Male Subjects

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vonoprazan (Primary) ; Aspirin; Diclofenac; Loxoprofen; Meloxicam
  • Indications Duodenal ulcer; Erosive oesophagitis; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; Peptic ulcer; Reflux oesophagitis
  • Focus Pharmacokinetics
  • Sponsors Takeda Pharma

    • Most Recent Events

    • 31 Aug 2016 Results published in the Clinical Drug Investigation
    • 16 Jun 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top